News

Search:

Meeting to Focus on Regulatory Paradigm of Developing, Evaluating ALS Therapies

1 Likes

The US Food and Drug Administration (FDA) will soon hold a public meeting to obtain input on ways to enhance the development of new therapies to treat amyotrophic lateral sclerosis (ALS), better known Read More...

Tags:

ALS

FDA

Lou Gehrig's Disease

Meeting

Nerve

Regulatory

Rilutek

FDA Panel Recommends Restarting Testing of Controversial Pain Drugs

0 Likes

An US Food and Drug Administration (FDA) Advisory Committee Panel recommended clinical trials testing anti-nerve growth factor inhibitors (anti-NGF inhibitors) be allowed to continue, with certain Read More...

Tags:

AAC

AdComm

Advisory Committee

Anti-NGF

Arthritis

CDER

Clinical Trials

Drugs

FDA

Nerve

Pain

Pharmaceuticals

RF Today is Regulatory Focus' daily news brief. Each edition contains the top global regulatory news stories about pharmaceuticals, medical devices, biotechnology and more. Learn more

Most Viewed
Most Popular

Most Viewed

China's SFDA Becomes CFDA amidst Consolidation of Power and New Leadership 25 March 2013
FDA Plans Huge Cardiovascular Registry With Focus on Medical Devices 2 April 2013
In Unprecedented Shift, EU Parliament Proposes Premarket Authorization for Medical Devices 15 April 2013
Goodbye, KFDA: Korean Regulator Gets New Name, Decentralized Authority After Reorganization 28 March 2013
FDA Gets Go-Ahead for Study of DTC Advertising and Social Media 18 April 2013
UPDATED: President's Budget Proposal Calls for Small Increases at FDA, but Big Changes for Industry 11 April 2013
IBM Awarded Huge Contract to Modernize Regulatory Review Processes at FDA 29 April 2013
New FDA Document Clarifies IND Process for Drugs, Biologics and Biosimilars 30 April 2013

New Regulatory Focus Apps for iPad and iPhone

Stay Connected:

Regulatory Focus is for regulatory professionals written by regulatory professionals.

The publication takes a look at the important topics facing regulatory professionals in a changing global healthcare landscape. From topics ranging from research and development to labeling and marketing, the articles try to analyze, inform, and educate readers about the issues at the forefront of the industry.

Rated as the number one benefit by the members of RAPS, Regulatory Focus strives to provide the best and most current information to regulatory professionals so they can succeed and advance at every stage in their careers.

For questions or comments on our content or to find out more about Regulatory Focus, please visit our About RF page.

News

Meeting to Focus on Regulatory Paradigm of Developing, Evaluating ALS Therapies

FDA Panel Recommends Restarting Testing of Controversial Pain Drugs

Get RF Today